# Immunotherapy in Patients With Early dMMR Rectal Cancer

Source: https://onco.cc/trials/nct05732389/  
OnCo record `nct05732389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nivolumab and ipilimumab in colorectal cancer, run by Odense University Hospital, now recruiting.

## Summary

Immunotherapy in Patients With Early dMMR Rectal Cancer is a phase 2, interventional study registered as NCT05732389 by Odense University Hospital, with a registry enrolment figure of 39 participants, started 2023-02-01 and due to reach its primary completion in 2027-07. Interventions recorded: Nivolumab; Ipilimumab. Conditions listed: Cancer of Rectum. Primary outcome: Complete clinical response. Colorectal eligibility wording from the registry: "* Histologically verified non-metastatic rectal cancer stage 1-3". Sites: Denmark. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: RESET-R
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05732389
- Phase: 2
- Setting: Immunotherapy in Patients With Early dMMR Rectal Cancer
- Sponsor: Odense University Hospital
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT05732389: https://clinicaltrials.gov/study/NCT05732389

## Connected records

- cancers: [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05732389.json